116 related articles for article (PubMed ID: 26704012)
1. [Impact of platelet count on prognosis of stage II-III colorectal cancer receiving adjuvant chemotherapy].
Wei Y; Liang Z; Hong C; Luo D; Cai Z; Guan H; Zeng Z; Yang Z; Luo P; Tan Z
Zhonghua Wei Chang Wai Ke Za Zhi; 2015 Dec; 18(12):1261-4. PubMed ID: 26704012
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.
André T; de Gramont A; Vernerey D; Chibaudel B; Bonnetain F; Tijeras-Raballand A; Scriva A; Hickish T; Tabernero J; Van Laethem JL; Banzi M; Maartense E; Shmueli E; Carlsson GU; Scheithauer W; Papamichael D; Möehler M; Landolfi S; Demetter P; Colote S; Tournigand C; Louvet C; Duval A; Fléjou JF; de Gramont A
J Clin Oncol; 2015 Dec; 33(35):4176-87. PubMed ID: 26527776
[TBL] [Abstract][Full Text] [Related]
3. The impact of chemotherapy-associated neutrophil/ lymphocyte counts on prognosis of adjuvant chemotherapy in colorectal cancer.
Chu-Yuan H; Jing P; Yi-Sheng W; He-Ping P; Hui Y; Chu-Xiong Z; Guo-Jian L; Guo-Qiang W
BMC Cancer; 2013 Apr; 13():177. PubMed ID: 23551939
[TBL] [Abstract][Full Text] [Related]
4. KRAS mutation is associated with worse prognosis in stage III or high-risk stage II colon cancer patients treated with adjuvant FOLFOX.
Lee DW; Kim KJ; Han SW; Lee HJ; Rhee YY; Bae JM; Cho NY; Lee KH; Kim TY; Oh DY; Im SA; Bang YJ; Jeong SY; Park KJ; Park JG; Kang GH; Kim TY
Ann Surg Oncol; 2015 Jan; 22(1):187-94. PubMed ID: 24889488
[TBL] [Abstract][Full Text] [Related]
5. Defective mismatch repair status as a prognostic biomarker of disease-free survival in stage III colon cancer patients treated with adjuvant FOLFOX chemotherapy.
Zaanan A; Fléjou JF; Emile JF; Des GG; Cuilliere-Dartigues P; Malka D; Lecaille C; Validire P; Louvet C; Rougier P; de Gramont A; Bonnetain F; Praz F; Taïeb J
Clin Cancer Res; 2011 Dec; 17(23):7470-8. PubMed ID: 21998335
[TBL] [Abstract][Full Text] [Related]
6. Effect of Adjuvant FOLFOX Chemotherapy Duration on Outcomes of Patients With Stage III Colon Cancer.
Kumar A; Peixoto RD; Kennecke HF; Renouf DJ; Lim HJ; Gill S; Speers CH; Cheung WY
Clin Colorectal Cancer; 2015 Dec; 14(4):262-8.e1. PubMed ID: 26123496
[TBL] [Abstract][Full Text] [Related]
7. The impact of chemotherapy-associated hemoglobin on prognosis of colorectal cancer patients receiving adjuvant chemotherapy.
Wei YS; Zhou YG; Wang GY; Liang ZH; Luo MR; Yang TA; Huang J
Cancer Biomark; 2017 Dec; 20(4):627-635. PubMed ID: 28800321
[TBL] [Abstract][Full Text] [Related]
8. T4 stage and preoperative anemia as prognostic factors for the patients with colon cancer treated with adjuvant FOLFOX chemotherapy.
An MS; Yoo JH; Kim KH; Bae KB; Choi CS; Hwang JW; Kim JH; Kim BM; Kang MS; Oh MK; Hong KH
World J Surg Oncol; 2015 Feb; 13():64. PubMed ID: 25889520
[TBL] [Abstract][Full Text] [Related]
9. Methylation and microsatellite status and recurrence following adjuvant FOLFOX in colorectal cancer.
Han SW; Lee HJ; Bae JM; Cho NY; Lee KH; Kim TY; Oh DY; Im SA; Bang YJ; Jeong SY; Park KJ; Park JG; Kang GH; Kim TY
Int J Cancer; 2013 May; 132(9):2209-16. PubMed ID: 23034738
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of mucinous histology depends on microsatellite instability status in patients with stage III colon cancer treated with adjuvant FOLFOX chemotherapy: a retrospective cohort study.
Kim SH; Shin SJ; Lee KY; Kim H; Kim TI; Kang DR; Hur H; Min BS; Kim NK; Chung HC; Roh JK; Ahn JB
Ann Surg Oncol; 2013 Oct; 20(11):3407-13. PubMed ID: 23943026
[TBL] [Abstract][Full Text] [Related]
11. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial.
Hong YS; Nam BH; Kim KP; Kim JE; Park SJ; Park YS; Park JO; Kim SY; Kim TY; Kim JH; Ahn JB; Lim SB; Yu CS; Kim JC; Yun SH; Kim JH; Park JH; Park HC; Jung KH; Kim TW
Lancet Oncol; 2014 Oct; 15(11):1245-53. PubMed ID: 25201358
[TBL] [Abstract][Full Text] [Related]
12. [Prognostic analysis of 443 cases of stage II colorectal cancer and the value of adjuvant chemotherapy].
Zhou ZG; Pan ZZ; Wan DS; Li LR; Wu XJ; Ding PR; Lin JZ; Peng ZH
Ai Zheng; 2009 Sep; 28(9):908-12. PubMed ID: 19728905
[TBL] [Abstract][Full Text] [Related]
13. [Clinical observation of XELOX (Capecitabine puls Oxaliplatin): an adjuvant chemotherapy regimen used in stage III colorectal cancer].
Diao C; Cheng RC; Zhang JM; Wei XP; Su YJ; Liu QY; Xu JB
Zhonghua Zhong Liu Za Zhi; 2008 Feb; 30(2):147-50. PubMed ID: 18646702
[TBL] [Abstract][Full Text] [Related]
14. The association between neutropenia and prognosis in stage III colorectal cancer patients receiving adjuvant chemotherapy.
Sunaga T; Suzuki S; Kogo M; Kurihara T; Kaji S; Koike N; Harada N; Suzuki M; Kiuchi Y
Eur J Cancer Care (Engl); 2014 May; 23(3):394-400. PubMed ID: 24033646
[TBL] [Abstract][Full Text] [Related]
15. Prognostic influence of body mass index and body weight gain during adjuvant FOLFOX chemotherapy in Korean colorectal cancer patients.
Lee DW; Han SW; Cha Y; Lee KH; Kim TY; Oh DY; Im SA; Bang YJ; Park JW; Ryoo SB; Jeong SY; Kang GH; Park KJ; Kim TY
BMC Cancer; 2015 Oct; 15():690. PubMed ID: 26467912
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Implications of Chemotherapy-Induced Neutropenia in Stage III Colorectal Cancer.
Kim S; Kang SI; Kim S; Kim JH
J Surg Res; 2021 Nov; 267():391-396. PubMed ID: 34218138
[TBL] [Abstract][Full Text] [Related]
17. Microsatellite Instability was not Associated with Survival in Stage III Colon Cancer Treated with Adjuvant Chemotherapy of Oxaliplatin and Infusional 5-Fluorouracil and Leucovorin (FOLFOX).
Kim JE; Hong YS; Kim HJ; Kim KP; Kim SY; Lim SB; Park IJ; Kim CW; Yoon YS; Yu CS; Kim JC; Kim JH; Kim TW
Ann Surg Oncol; 2017 May; 24(5):1289-1294. PubMed ID: 27853901
[TBL] [Abstract][Full Text] [Related]
18. Practical outcome of adjuvant FOLFOX4 chemotherapy in elderly patients with stage III colon cancer: single-center study in Korea.
Kim JY; Kim YJ; Lee KW; Lee JS; Kim DW; Kang SB; Lee HS; Jang NY; Kim JS; Kim JH
Jpn J Clin Oncol; 2013 Feb; 43(2):132-8. PubMed ID: 23204187
[TBL] [Abstract][Full Text] [Related]
19. LINE-1 Methylation Status Correlates Significantly to Post-Therapeutic Recurrence in Stage III Colon Cancer Patients Receiving FOLFOX-4 Adjuvant Chemotherapy.
Lou YT; Chen CW; Fan YC; Chang WC; Lu CY; Wu IC; Hsu WH; Huang CW; Wang JY
PLoS One; 2014; 10(4):e0123973. PubMed ID: 25919688
[TBL] [Abstract][Full Text] [Related]
20. Preoperative Serum Carcinoembryonic Antigen Level as a Prognostic Factor for Recurrence and Survival After Curative Resection Followed by Adjuvant Chemotherapy in Stage III Colon Cancer.
Kim CG; Ahn JB; Jung M; Beom SH; Heo SJ; Kim JH; Kim YJ; Kim NK; Min BS; Koom WS; Kim H; Roh YH; Ma BG; Shin SJ
Ann Surg Oncol; 2017 Jan; 24(1):227-235. PubMed ID: 27699609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]